Estrogen Patch Shortage May Last Over a Year Amid Demand Surge
A spike in menopause treatment demand has left estrogen patches in short supply, and manufacturers warn resolution could take more than a year.
Estrogen patches used to treat menopause symptoms are increasingly difficult to find across the United States, as surging patient demand has outpaced manufacturers' ability to keep shelves stocked — and relief may not come for at least 12 months, according to reports.
The shortage reflects a broader acceleration in menopause-related healthcare awareness, with more women and clinicians actively seeking hormone therapy options in recent years. That cultural shift has translated into a sharp uptick in prescriptions that supply chains were simply not built to absorb at current scale.
Read more Should High Earners Delay Social Security Benefits? What to Know →
Manufacturers are under pressure to expand production capacity, but pharmaceutical output cannot be scaled overnight. Regulatory requirements, raw material sourcing, and facility constraints all slow the timeline, meaning patients who rely on transdermal estrogen therapy may face ongoing disruptions well into the foreseeable future.
The ripple effects are already being felt at the pharmacy level, where pharmacists are fielding calls from patients unable to fill prescriptions and physicians are scrambling to identify alternative formulations. The situation puts particular stress on patients managing perimenopause or postmenopause symptoms who depend on consistent hormone levels for quality of life.
Healthcare providers are urging patients not to abruptly discontinue therapy without consulting a doctor, and some are exploring compounded alternatives as a stopgap while the market works to rebalance. Continue reading at US Top News and Analysis.
